CASP3 and metabolic dysfunction-associated steatohepatitis: However, a recent study using the pan-caspase inhibitor emricasan in NASH patients failed to improve disease activity and fibrosis and suggested that inhibition of the main apoptotic caspases 3 and 7 resulted in a shift to other types of cell death [20].